MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.cct.2025.108170

Медицинская библиотека · Contemporary clinical trials · 2025

Assessment of a novel functional food modulating the microbiota-inflammation-brain axis in patients with heart failure and/or /atrial fibrillation patients (the AMBROSIA study): Protocol for a randomized controlled trial.

Baldi Simone, Cuffaro Francesca, Russo Edda, Porter Kate, Cheung William, Coman Maria Magdalena, Vaquero Marco Garcia, Lingner Thomas, Verdenelli Maria Cristina, Barceló-Coblijn Gwendolyn, Brownlee Iain, Fumagalli Stefano, Amedei Amedeo

СтатьяПротокол клинического исследованияПеревод в очереди

Аннотация

BACKGROUND AND AIMS: Atrial fibrillation (AF), heart failure (HF), and undernutrition represent a complex triad with major clinical and socioeconomic consequences in older adults, often predisposing to frailty. Undernutrition often remains underdiagnosed due to a reliance on weight-based measures and limited awareness of inflammation-related cachexia. The AMBROSIA study aims to fill these gaps by exploring the response of the microbiota-inflammation-brain axis to a targeted, fortified food product-based intervention, with comprehensive outcome assessments, alongside mechanistic/exploratory -omics analyses and gut microbiota (GM) functional profiling.

METHODS AND

RESULTS

This single-center, prospective, parallel-group randomized controlled trial aims to enroll 120 older adults with confirmed AF and/or HF. Participants will be randomized 1:1 into an intervention group (n = 60) or control group (n = 60). All participants receive individualized dietary counseling; the intervention group additionally consumes one AMBROSIA nutritional bar daily for six months. The bar contains hydrolyzed proteins, inulin, CoQ₁₀, and probiotics (L. rhamnosus IMC 501® and L. paracasei IMC 502®) in a flavonoid-rich chocolate matrix. Clinical, cognitive, and nutritional data, along with blood, saliva, urine, and stool samples, will be collected at baseline, 3, and 6 months. The primary endpoint is the change in skeletal muscle mass, physical function and frailty, while secondary endpoints include changes in nutritional status, inflammation, GM, metabolomics, and quality of life.

CONCLUSION

By integrating cutting-edge omics tools and a multidimensional nutritional strategy, AMBROSIA aims to uncover mechanisms driving undernutrition and identify biomarkers to support personalized interventions for older patients with AF and HF.

Для цитирования: Baldi Simone, Cuffaro Francesca, Russo Edda, Porter Kate, Cheung William, Coman Maria Magdalena, Vaquero Marco Garcia, Lingner Thomas, Verdenelli Maria Cristina, Barceló-Coblijn Gwendolyn, Brownlee Iain, Fumagalli Stefano, Amedei Amedeo. Assessment of a novel functional food modulating the microbiota-inflammation-brain axis in patients with heart failure and/or /atrial fibrillation patients (the AMBROSIA study): Protocol for a randomized controlled trial.. Contemporary clinical trials. 2025. DOI: 10.1016/j.cct.2025.108170.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.